Revakinagene taroretcel, sold under the brand name Encelto, is an allogeneic encapsulated cell-based gene therapy used for the treatment of macular telangiectasia type 2. Revakinagene taroretcel is administered into the recipient's eye during a single surgical procedure. Revakinagene taroretcel works by expressing recombinant human ciliary neurotrophic factor, which is a factor that may promote the survival and maintenance of the macular photoreceptors. Revakinagene taroretcel was approved for medical use in the United States in March 2025.
Medical uses Revakinagene taroretcel is indicated for the treatment of adults with idiopathic macular telangiectasia type 2. Macular telangiectasia type 2 is a rare progressive disease of the macula (portion of the eye that process sharp central vision), leading to degeneration of the photoreceptors which are specialized light-detecting cells in the back of the eye.
Society and culture
Legal status Revakinagene taroretcel was approved for medical use in the United States in March 2025.
Names Revakinagene taroretcel is the international nonproprietary name and the United States Adopted Name.
References
External links Clinical trial number NCT03316300 for "A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A" at ClinicalTrials.gov Clinical trial number NCT03319849 for "A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B" at ClinicalTrials.gov
